Advertisement Basilea launches Zevtera in Germany - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Basilea launches Zevtera in Germany

Switzerland-based Basilea Pharmaceutica has launched its broad-spectrum antibiotic, Zevtera (ceftobiprole medocaril) in Germany to support the treatment of bacterial lung infections.

According to the European Centre for Disease Prevention and Control (ECDC), every year about 25,000 people die from antibiotic-resistant healthcare-associated infections in the EU.

Basilea chief commercial officer David Veitch said: "Zevtera provides physicians with a simplified empiric treatment option with its broad-spectrum activity reducing the need for combination treatments. This is an important advance in the empirical treatment of pneumonia.

"Post-hoc analyses of phase 3 study data showed a more rapid effect for ceftobiprole as compared with a standard antibiotic combination in the treatment of hospital-acquired pneumonia.

"An early improvement of patients’ overall clinical condition may translate into additional benefits, especially in an intensive care unit setting, such as the potential for earlier mobilization or discharge of the patient to a general ward."

Zevtera is the only antibiotic monotherapy that is approved in certain European countries to treat adults with community-acquired pneumonia and hospital-acquired pneumonia with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens including Pseudomonas spp.

Ceftobiprole is a new generation broad-spectrum cephalosporin antibiotic with rapid bactericidal activity against Gram-positive and Gram-negative bacteria associated with pneumonia, including MRSA and Pseudomonas spp.